# Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects

> **NCT04966325** · EARLY_PHASE1 · COMPLETED · sponsor: **LG Chem** · enrollment: 37 (actual)

## Conditions studied

- Hyperuricemia
- Gout
- Qt Interval, Variation in

## Interventions

- **DRUG:** LC350189 200mg
- **DRUG:** Placebo
- **DRUG:** Moxifloxacin 400mg
- **DRUG:** LC350189 600mg

## Key facts

- **NCT ID:** NCT04966325
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-23
- **Primary completion:** 2021-12-07
- **Final completion:** 2021-12-07
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2022-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04966325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04966325, "Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04966325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*